Business Context and Reporting Period
This Form 8-K reports the completion of a business combination between Liminatus Pharma, LLC ("Liminatus") and Iris Acquisition Corp ("Iris") on April 30, 2025. Following the closing, the combined entity operates as Liminatus Pharma, Inc., a pre-clinical, pre-revenue life sciences company developing a next-generation CD47 checkpoint inhibitor. The company's common stock (LIMN) and warrants (LIMNW) began trading on The Nasdaq Stock Market on May 1, 2025.
Key Financial Metrics
Revenue and Profitability: The company has generated no revenue to date and does not expect revenue from product sales in the foreseeable future. For the fiscal years ended December 31, 2024, and 2023, Liminatus reported net losses of $3.5 million and $5.0 million, respectively, with an accumulated deficit of $28.7 million as of December 31, 2024.
Cash Flow and Liquidity: As of December 31, 2024, Liminatus held approximately $56,000 in cash. Post-combination, on a pro forma basis, the company reported approximately $12.0 million in cash and cash equivalents. Net cash used in operating activities was $1.5 million for 2024 compared to $3.3 million in 2023.
Debt and Financing: The company has funded operations through equity sales ($4.5 million gross proceeds) and debt issuance ($20.0 million in bonds and notes through 2024). Significant debt obligations include $10.0 million in bonds to Feelux Co., Ltd. and various loans from related parties (Valetudo, Prophase, Amantes, Hana). A $15.0 million PIPE investment was completed concurrently with the closing.
Merger Consideration: Liminatus securityholders received 17.5 million shares of ParentCo Common Stock, valued at $175.0 million based on a $10.00 per share price.
Material Changes vs. Prior Period
- Corporate Structure: Transitioned from a private LLC to a public corporation (Liminatus Pharma, Inc.) via a SPAC merger.
- Operating Expenses: Research and development expenses decreased by $1.1 million in 2024 ($2.7 million) compared to 2023 ($3.8 million), primarily due to the termination of the CAR-T and Vaccine licenses with TDT. General and administrative expenses decreased by $0.4 million to $0.6 million.
- License Portfolio: The CAR-T and Vaccine licenses with TDT were terminated in August 2024. The company currently focuses on the CD47 License acquired from InnoBation/Valetudo.
- Capitalization: Public stockholders redeemed 59,844 shares for approximately $702,359. The Sponsor forfeited 4,177,778 private placement warrants.
Outlook, Risks, and Contingencies
Going Concern: The company has concluded there is substantial doubt about its ability to continue as a going concern within one year of the issuance of its financial statements without additional financing. It anticipates needing substantial additional funding for clinical trials and operations.
Outlook: Management expects expenses to increase significantly as the company advances clinical trials for its CD47 product candidate. The company does not expect to generate revenue unless and until it obtains regulatory approval and commercializes its product.
Risks and Contingencies:
- Debt Obligations: The company has numerous loans with related parties that were deferred until the business combination closing. These amounts remain due and payable post-closing.
- Legal Disputes: As of December 31, 2024, the company and TDT were negotiating amounts due following the termination of their license agreements. Approximately $2.2 million was accrued, though the final amount remains uncertain.
- Regulatory and Development Risk: As a pre-clinical company, there is no assurance that product candidates will achieve regulatory approval or commercial success.
Investor Verification Checklist
- Verify the pro forma cash position of approximately $12.0 million and the timeline for funding operations beyond the next 12 months.
- Review the status of the $2.2 million accrued liability to TDT and the outcome of ongoing negotiations regarding the terminated licenses.
- Confirm the terms and repayment schedules of the various related-party loans (Valetudo, Prophase, Amantes, Hana) that were deferred during the merger process.
- Assess the progress of the CD47 product candidate in pre-clinical stages and the timeline for initiating clinical trials.
- Examine the lock-up agreements restricting the sale of shares by Liminatus members and the Sponsor for periods ranging from six to twenty-four months.